We are live on
!
Find out more
PCM
Pavaki Capital Management Portfolio holdings
AUM
$287M
This Fund
S&P 500
This Quarter
Est. Return
+12.26%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$255M
AUM Growth
–
Cap. Flow
+$138M
Cap. Flow
% of AUM
54.05%
Top 10 Holdings %
Top 10 Hldgs %
57.32%
Holding
131
New
131
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Milestone Pharmaceuticals
MIST
|
+$18.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$13.2M |
| 3 |
ARS Pharmaceuticals
SPRY
|
+$11.4M |
| 4 |
B
Barrick Mining
B
|
+$7.28M |
| 5 |
Walt Disney
DIS
|
+$6.72M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 44.5% |
| 2 | Healthcare | 29.54% |
| 3 | Materials | 10.85% |
| 4 | Communication Services | 4.97% |
| 5 | Technology | 3.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Carvana
CVNA
$45.8B
| $48.5M | 19.01% |
+575,000
| New | +$42.7M |
|
|
2
Milestone Pharmaceuticals
MIST
$102M
| $17.2M | 6.73% |
+8,498,915
| New | +$18.3M |
|
3
CALL
Tesla
TSLA
$1.39T
| $16.9M | 6.61% |
+37,500
| New | +$16.6M |
|
|
4
Regeneron Pharmaceuticals
REGN
$77.3B
| $15M | 5.87% |
+19,400
| New | +$13.2M |
|
|
5
ARS Pharmaceuticals
SPRY
$438M
| $13.7M | 5.35% |
+1,172,000
| New | +$11.4M |
|
6
CALL
Palantir
PLTR
$449B
| $8.62M | 3.38% |
+48,500
| New | +$8.78M |
|
|
B
7
Barrick Mining
B
$67.9B
| $8.45M | 3.31% |
+194,000
| New | +$7.28M |
|
|
8
Walt Disney
DIS
$182B
| $6.94M | 2.72% |
+61,000
| New | +$6.72M |
|
9
Arcutis Biotherapeutics
ARQT
$3.36B
| $5.87M | 2.3% |
+202,000
| New | +$5.17M |
|
10
B2Gold
BTG
$7.05B
| $5.23M | 2.05% |
+1,160,000
| New | +$5.41M |
|
11
Organon & Co
OGN
$3.61B
| $5.22M | 2.05% |
+728,100
| New | +$5.75M |
|
12
CALL
Applovin
APP
$102B
| $4.18M | 1.64% |
+6,200
| New | +$3.91M |
|
|
13
PUT
Carvana
CVNA
$45.8B
| $3.8M | 1.49% |
+45,000
| New | +$3.35M |
|
14
Textron
TXT
$13.4B
| $3.72M | 1.46% |
+42,700
| New | +$3.57M |
|
15
Intel
INTC
$613B
| $3.69M | 1.45% |
+100,000
| New | +$3.78M |
|
16
Newmont
NEM
$123B
| $3.25M | 1.27% |
+32,500
| New | +$2.94M |
|
17
PUT
Invesco QQQ Trust
QQQ
$495B
| $3.07M | 1.2% |
+5,000
| New | +$3.07M |
|
18
NVIDIA
NVDA
$5.49T
| $2.98M | 1.17% |
+16,000
| New | +$2.98M |
|
|
CGAU
19
Centerra Gold
CGAU
$4.31B
| $2.83M | 1.11% |
+197,000
| New | +$2.47M |
|
|
PSKY
20
Paramount Skydance Corp
PSKY
$11.2B
| $2.8M | 1.1% |
+208,863
| New | +$3.26M |
|
|
21
CALL
Invesco QQQ Trust
QQQ
$495B
| $2.76M | 1.08% |
+4,500
| New | +$2.76M |
|
22
Harmony Biosciences
HRMY
$2.29B
| $2.73M | 1.07% |
+73,000
| New | +$2.4M |
|
23
CALL
Broadcom
AVGO
$1.7T
| $2.42M | 0.95% |
+7,000
| New | +$2.5M |
|
24
Douglas Elliman
DOUG
$138M
| $2.4M | 0.94% |
+1,013,552
| New | +$2.61M |
|
25
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $2.18M | 0.86% |
+3,200
| New | +$2.16M |
|
Similar funds
OCM
RSC
MC
QFW
SRWM
ORC
MPAM
AWMT
Pavaki Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Pavaki Capital Management, which disclosed 131 positions worth $255M. Its ten largest holdings account for 57% of the portfolio.
Its largest position is Milestone Pharmaceuticals: 8,498,915 shares worth $17.2M.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, followed by Healthcare and Materials.
- Pavaki Capital Management's largest Q4 2025 buy was Milestone Pharmaceuticals: 8,498,915 shares worth $17.2M.
- Pavaki Capital Management's ten largest holdings make up 57% of its $255M portfolio in Q4 2025.
- Pavaki Capital Management disclosed 131 positions in Q4 2025, its first 13F filing on record.
Based on Pavaki Capital Management's 13F filing for Q4 2025, filed 7 Aug 2026.